Via Separations

Membrane technology for industrial filtration solutions

Watertown, Massachusetts, United States

About Via Separations

Via Separations specializes in industrial filtration technology, focusing on improving process efficiency and reducing costs for various industries. The company's main product is an advanced membrane platform that enhances filtration processes by using better materials. This technology can cut energy consumption by up to 90% compared to traditional thermal separation methods, which are widely used in industries like chemical manufacturing, food and beverage processing, pharmaceuticals, and water treatment. Via Separations differentiates itself from competitors by offering a unique membrane solution that not only saves energy but also boosts operational efficiency. The company aims to provide substantial energy savings and cost-effective separation methods to its clients, generating revenue through product sales, installation, maintenance services, and licensing agreements.

Watertown, MassachusettsHeadquarters
2017Year Founded
$55.7MTotal Funding
GRANTCompany Stage
Industrial & Manufacturing, EnergyIndustries
11-50Employees

Benefits

Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
12+ weeks of paid Family Leave
Paid Flex time off
Paid time off for Company holidays
Company Equity

Risks

Increased competition may impact Via's market share and pricing.
Dependence on government funding poses risks if policy shifts occur.
Economic downturns in key industries could reduce demand for Via's products.

Differentiation

Via Separations offers a novel membrane technology reducing energy use by 90%.
The company targets 12% of US energy wasted in chemical separations annually.
Via's technology is spun out of MIT, scaling up over 10 million times.

Upsides

Growing demand for sustainable processes boosts Via's membrane technology adoption.
Government incentives for clean energy support Via's scaling efforts.
Pulp and paper industry adoption aligns with Via's pilot trials.